The Company	3 Months Ended
Mar. 31, 2015
The Company
The Company	1. The Company Business Momenta Pharmaceuticals, Inc. (the “Company” or “Momenta”) was incorporated in the state of Delaware in May 2001 and began operations in early 2002. Its facilities are located in Cambridge, Massachusetts. Momenta is a biotechnology company focused on developing generic versions of complex drugs, biosimilars and novel therapeutics for oncology and autoimmune disease. The Company presently derives all of its revenue from its collaborations. Please see Note 10 “Subsequent Events” for information regarding marketing approval of Glatopa™ (glatiramer acetate injection) (formerly M356), the Company’s generic equivalent of once-daily COPAXONE® 20 mg/mL, by the U.S. Food and Drug Administration on April 16, 2015. M356 now refers only to the generic version of three-times-weekly COPAXONE 40 mg/mL being developed by the Company.

The Company

3 Months Ended

Mar. 31, 2015

1. The Company

Business

Momenta Pharmaceuticals, Inc. (the “Company” or “Momenta”) was incorporated in the state of Delaware in May 2001 and began operations in early 2002. Its facilities are located in Cambridge, Massachusetts. Momenta is a biotechnology company focused on developing generic versions of complex drugs, biosimilars and novel therapeutics for oncology and autoimmune disease. The Company presently derives all of its revenue from its collaborations.

Please see Note 10 “Subsequent Events” for information regarding marketing approval of Glatopa™ (glatiramer acetate injection) (formerly M356), the Company’s generic equivalent of once-daily COPAXONE® 20 mg/mL, by the U.S. Food and Drug Administration on April 16, 2015. M356 now refers only to the generic version of three-times-weekly COPAXONE 40 mg/mL being developed by the Company.